摘要
卡非佐米是经静脉给药的第二代蛋白酶体抑制剂,具有良好的抗肿瘤活性,用于治疗预先接受过至少2种药物治疗(包括第一代蛋白酶体抑制剂硼替佐米和一种免疫调节剂),并有证据显示在完成末次治疗后60 d内疾病恶化的难治性多发性骨髓瘤,于2012年7月20日由美国食品和药物管理局(FDA)批准上市。其最为常见的不良反应为疲乏、贫血、恶心、血小板减少、呼吸困难、腹泻以及发热等。本文通过Medline对卡非佐米进行文献检索,并对其药理作用、药效学、药动学、临床评价、用法用量、药物相互作用和安全性进行了综述。
Carfilzomib is a second-generation proteasome inhibitor administered intravenously with well- documented anticancer activities. Carfilzomib is approved by FDA on July 20, 2012. It is indicated for the treat- ment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy. The most common adverse reactions include fatigue, anemia, nausea, thrombocytopenia, dyspnea and fe- ver. A literature search was conducted using Medline with the key words carfilzomib. Its pharmacology, pharmacody- namics, pharmacokinetics, the treatment of clinical, dosage, drug interactions and safety were reviewed in this paper.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2013年第13期1479-1482,共4页
Chinese Journal of New Drugs
